Targeting the akt/mtor signaling pathway by maprotiline leads to tumor suppression in T-cell lymphoma.

ABSTRACT: T-cell lymphoma (TCL) is a prevalent malignancy characterized by the aberrant proliferation of T cells. The molecular mechanism underlying TCL remains poorly understood, and effective therapeutic strategies are still limited. Maprotiline, a highly selective norepinephrine reuptake blocker, is primarily used in the treatment of various types of depression. Intriguingly, its potential therapeutic utility and underlying mechanisms in TCL have not been previously explored. In this study, we demonstrated for the first time that maprotiline significantly inhibits proliferation and migration while promoting apoptosis in TCL cells. Furthermore, in vivo experiments using TCL xenograft mouse models revealed that maprotiline treatment effectively suppresses tumor progression while maintaining a favor

SUBMITTER: Li X 

PROVIDER: S-EPMC12672815 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature